ADC

5개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs
ADCStandard DatabasestaleAbbViePhase 3

Mirvetuximab soravtansine plus Bevacizumab (Mirvetuximab soravtansine plus Bevacizumab)

Ovarian Cancer; Peritoneal Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase3#antibody-drug-conjugate#PeritonealCancer+1
Trials 6Status Recruiting
ADCLimited DatastaleGenmabPhase 2

HuMax-AXL-ADC (Enapotamab vedotin, Enapotamab vedotin (HuMax-AXL-ADC))

Ovarian Cancer; Cervical Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#CervicalCancer+1
Trials 1Status Active
ADCLimited DatastaleAbbViePhase 1

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)

Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase1#antibody-drug-conjugate#FallopianTubeCancer+1
Trials 1Status Active
ADCLimited DatastaleThe First Affiliated Hospital o…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Combined with Bevacizumab)

Platinum-resistant Recurrent Ovarian Cancer (PROC) · Platinum-resistant Recurrent Ovarian Can

#Platinum-resistantRecurrentOvari#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
ADCLimited DatastaleBoryung Pharmaceutical Co., LtdPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#OvarianCarcinoma+2
Trials 1Status Recruiting